Identification

Name
Hyoscyamine
Accession Number
DB00424  (APRD00607)
Type
Small Molecule
Groups
Approved
Description

Hyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine. It is a secondary metabolite of some plants, particularly henbane (Hyoscamus niger.) Hyoscyamine is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, pancreatitis, colic and cystitis. It has also been used to relieve some heart problems, control some of the symptoms of Parkinson's disease, as well as for control of respiratory secretions in end of life care.

Structure
Thumb
Synonyms
  • (−)-atropine
  • (−)-hyoscyamine
  • (S)-(−)-hyoscyamine
  • (S)-atropine
  • [3(S)-endo]-α-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester
  • Daturin
  • Daturine
  • Duboisine
  • Hyoscyamin
  • Hyoscyamine
  • Hyoscyaminum
  • L-Hyoscyamine
  • L-Tropine tropate
  • Tropine-L-tropate
Product Ingredients
IngredientUNIICASInChI Key
Hyoscyamine hydrobromideIWT50P9S79306-03-6VZDNSFSBCMCXSK-PGQIENJJSA-N
Hyoscyamine sulfateOB570Z127K620-61-1Not applicable
Hyoscyamine sulfate dihydrateF2R8V82B846835-16-1BXSVDJUWKSRQMD-ITMJLNKNSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LevsinTablet0.125 mgOralSchwarz Pharma Kremers Urban Company1960-12-312008-08-08Canada
Levsin Drops 0.125mg/mlSolution / drops0.125 mgOralSchwarz Pharma Kremers Urban Company1982-12-311996-09-09Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calmitol Itching Relief OntHyoscyamine (.0001 %) + Camphor (.62 %) + Chloral hydrate (.496 %) + Menthol (.58 %) + Zinc oxide (12.5 %)OintmentTopicalPfizer Canada Inc., Consumer Healthcare Division1964-12-311996-09-09Canada
Diban CapHyoscyamine sulfate (0.0519 mg) + Atropine sulfate (9.7 mcg) + Attapulgite (300 mg) + Opium (12 mg) + Pectin (71.4 mg) + Scopolamine (3.3 mcg)CapsuleOralAyerst Laboratories1992-12-311999-04-12Canada
Diban CapHyoscyamine sulfate (0.0519 mg) + Atropine sulfate (9.7 mcg) + Attapulgite (300 mg) + Opium (12 mg) + Pectin (71.4 mg) + Scopolamine (3.3 mcg)CapsuleOralWyeth Ayerst Canada Inc.1998-02-182001-01-30Canada
Donnagel LiqHyoscyamine sulfate (0.1037 mg) + Atropine sulfate (0.0194 mg) + Kaolin (6 g) + Pectin (142.8 mg) + Scopolamine (6.5 mcg)LiquidOralWyeth Ayerst Canada Inc.1995-12-311997-08-14Canada
Donnagel LiqHyoscyamine sulfate (0.1037 mg) + Atropine sulfate (0.0194 mg) + Kaolin (6 g) + Pectin (142.8 mg) + Scopolamine (6.5 mcg)LiquidOralAyerst Laboratories1993-12-311996-09-10Canada
Donnatal ElixirHyoscyamine sulfate (0.1037 mg) + Atropine sulfate (0.0194 mg) + Phenobarbital (16.2 mg) + Scopolamine (6.5 mcg)ElixirOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal ElixirHyoscyamine sulfate (0.1037 mg) + Atropine sulfate (0.0194 mg) + Phenobarbital (16.2 mg) + Scopolamine (6.5 mcg)ElixirOralWyeth Ayerst Canada Inc.1994-12-312001-01-16Canada
Donnatal ExtentabsHyoscyamine sulfate (0.3111 mg) + Atropine sulfate (0.0582 mg) + Phenobarbital (48.6 mg) + Scopolamine (0.0195 mg)Tablet, extended releaseOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal Extentabs SrtHyoscyamine sulfate (0.3111 mg) + Atropine sulfate (0.0582 mg) + Phenobarbital (48.6 mg) + Scopolamine (0.0195 mg)Tablet, extended releaseOralWyeth Ayerst Canada Inc.1994-12-312001-05-07Canada
Donnatal TabHyoscyamine sulfate (0.1037 mg) + Atropine sulfate (0.0194 mg) + Phenobarbital (16.2 mg) + Scopolamine (6.5 mcg)TabletOralWyeth Ayerst Canada Inc.1994-12-312001-05-22Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AnaspazHyoscyamine sulfate dihydrate (0.125 mg/1)Tablet, orally disintegratingOral; SublingualBF ASCHER AND CO INC1973-01-02Not applicableUs
AnaspazHyoscyamine sulfate dihydrate (0.125 mg/1)Tablet, orally disintegratingOral; SublingualPhysicians Total Care, Inc.1973-01-022011-06-30Us
Azuphen MbHyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) + Phenyl salicylate (36 mg/1) + Sodium phosphate, monobasic, monohydrate (40.8 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282016-11-01Us
B-DonnaHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralWinder Laboratories, LLC2015-12-302016-03-03Us
Belladonna Alkaloids with PhenobarbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralWest-Ward Pharmaceuticals Corp1966-01-01Not applicableUs0143 114020170720 1564 4ev749
Belladonna Alkaloids with PhenobarbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralbryant ranch prepack1966-01-012015-05-01Us
Belladonna Alkaloids with PhenobartbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralPhysicians Total Care, Inc.2004-08-312013-01-15Us
Belladonna Alkaloids with PhenobartbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralRebel Distributors2004-08-31Not applicableUs
Belladonna Alkaloids with PhenobartbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralPreferreed Pharmaceuticals Inc.2004-08-312013-04-30Us
Belladonna Alkaloids with PhenobartbitalHyoscyamine sulfate dihydrate (0.1037 mg/1) + Atropine sulfate (0.0194 mg/1) + Phenobarbital (16.2 mg/1) + Scopolamine (0.0065 mg/1)TabletOralLegacy Pharmaceutical Packaging2000-12-01Not applicableUs
International/Other Brands
Acupaz (Glitz) / Anapaz (Hilton) / Anaspaz (Ascher) / Atropen / Boots Travel Calm (Boots) / Buwecon (Yung Shin) / Cystospaz / Cytospaz (Amerifit) / Donnamar / Egazil (BioPhausia) / Levbid / Levsinex / NuLev / Symax (Capellon)
Categories
UNII
PX44XO846X
CAS number
101-31-5
Weight
Average: 289.3694
Monoisotopic: 289.167793607
Chemical Formula
C17H23NO3
InChI Key
RKUNBYITZUJHSG-FXUDXRNXSA-N
InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16-/m1/s1
IUPAC Name
(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication

For treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Also used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis.

Associated Conditions
Pharmacodynamics

L-Hyoscyamine, the active optical isomer of atropine (dl-hyoscyamine), is a tertiary amine anticholinergic gastrointestinal agent.

Mechanism of action

Hyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
Absorption

Absorbed totally and completely by sublingual administration as well as oral administration.

Volume of distribution
Not Available
Protein binding

50%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

2-3.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. LD50=mg/kg(orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1,10-PhenanthrolineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with 1,10-Phenanthroline.
AbexinostatThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Acebutolol.
AceprometazineThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Aceprometazine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Acetyldigoxin.
AclidiniumThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Aclidinium.
AcrivastineThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Acrivastine.
AdenosineThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Adenosine.
AgmatineHyoscyamine may increase the anticholinergic activities of Agmatine.
AjmalineThe risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ajmaline.
Food Interactions
  • Take 30 minutes before meals, and at bedtime.

References

Synthesis Reference

Jeffrey Kiel, H. Thomas, Emily Ware, Brady Ware, "Phenolic acid complexes of hyoscyamine and process for preparing the same." U.S. Patent US20060128637, issued June 15, 2006.

US20060128637
General References
Not Available
External Links
Human Metabolome Database
HMDB0014568
KEGG Drug
D00147
KEGG Compound
C02046
PubChem Compound
154417
PubChem Substance
46507345
ChemSpider
10246417
ChEBI
17486
ChEMBL
CHEMBL1331216
Therapeutic Targets Database
DNC000758
PharmGKB
PA164776844
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Hyoscyamine
ATC Codes
A03BA03 — HyoscyamineA03CB31 — Hyoscyamine and psycholeptics
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Adenosquamous Lung Carcinoma / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Large Cell Lung Carcinoma / Minimally Invasive Lung Adenocarcinoma / Squamous Cell Carcinoma of Lung / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Lung Non-Small Cell Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
4RecruitingTreatmentLower Urinary Tract Symptoms (LUTS)1
Not AvailableRecruitingTreatmentFunctional Abdominal Pain / Functional Dyspepsia / Functional Gastrointestinal Disorders / Irritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • AG Marin Pharmaceuticals
  • Alaven Pharmaceutical
  • Allaire Pharmaceuticals
  • Alphagen Laboratories Inc.
  • Amerifit Inc.
  • Amerisource Health Services Corp.
  • Apicore LLC
  • Apotheca Inc.
  • Aristos Pharmaceuticals
  • Atlantic Biologicals Corporation
  • BF Ascher & Co.
  • Breckenridge Pharmaceuticals
  • Capellon Pharmaceuticals LLC
  • Cardinal Health
  • Cima Laboratories Inc.
  • Concord Labs
  • Contract Pharm
  • County Line Pharmaceuticals LLC
  • Cypress Pharmaceutical Inc.
  • Dayton Pharmaceuticals
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Econolab Inc.
  • Edwards Pharmaceuticals
  • Equipharm Inc.
  • Eros Pharma Private Ltd.
  • Ethex Corp.
  • Excellium Pharmaceutical Inc.
  • Franklin Pharmaceutical LLC
  • Great Southern Laboratories
  • Hi Tech Pharmacal Co. Inc.
  • Iopharm Laboratories Inc.
  • Jerome Stevens Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • KV Pharmaceutical Co.
  • Kylemore Pharmaceuticals
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Marlop Pharmaceuticals Inc.
  • Mckesson Corp.
  • Med Tek Pharmaceuticals Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • Physicians Total Care Inc.
  • Prasco Labs
  • Prescript Pharmaceuticals
  • Provident Pharmaceuticals LLC
  • Qualitest
  • RA McNeil Co.
  • Resource Optimization and Innovation LLC
  • River's Edge Pharmaceuticals
  • Sandhills Packaging Inc.
  • Schwarz Pharma Inc.
  • Seton Pharmaceuticals LLC
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • Sovereign Pharmaceuticals Ltd.
  • Spectrum Pharmaceuticals
  • Sunrise Pharmaceutical Inc.
  • Taylor Pharmaceuticals
  • United Research Laboratories Inc.
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
Dosage forms
FormRouteStrength
Tablet, orally disintegratingOral; Sublingual0.125 mg/1
OintmentTopical
CapsuleOral
LiquidOral
ElixirOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
TabletOral
TabletOral.125 mg/1
LiquidOral0.125 mg/1mL
LiquidOral0.125 mg/5mL
TabletSublingual0.125 mg/1
ElixirOral0.125 mg/5mL
ElixirOral25 mg/1mL
SolutionOral0.125 mg/1mL
Solution / dropsOral0.125 mg/1mL
TabletOral0.125 mg/1
TabletOral0.15 mg/1
TabletOral0.375 mg/1
TabletOral; Sublingual0.125 mg/1
Tablet, extended releaseOral0.375 mg/1
Tablet, multilayerOral.375 mg/1
Tablet, orally disintegratingOral0.125 mg/1
Tablet, orally disintegratingSublingual0.125 mg/1
Tablet, solubleOral0.125 mg/1
Injection, solutionSubcutaneous0.5 mg/1mL
TabletOral0.125 mg
Solution / dropsOral0.125 mg
Tablet, chewableOral0.125 mg/1
Tablet, coatedOral
Tablet, multilayer, extended releaseOral0.375 mg/1
Tablet, sugar coatedOral
Prices
Unit descriptionCostUnit
Levsin 0.125 mg/ml Solution 15ml Bottle49.09USD bottle
Levsin 0.5 mg/ml ampul27.33USD ml
Hyoscyamine sulfate powder25.69USD g
Symax Duotab 0.375 mg Controlled Release Tabs3.73USD tab
Symax-SL 0.125 mg Sublingual Tabs3.29USD tab
Symax duotab2.4USD tablet
Levbid 0.375 mg 12 Hour tablet2.12USD tablet
Levbid er 0.375 mg tablet2.09USD tablet
Hyoscyamine Sulfate CR 0.375 mg 12 Hour tablet1.66USD tablet
Levbid 0.375 mg tablet sa1.44USD tablet
Symax-sr 0.375 mg tablet1.4USD tablet
Levsin/SL 0.125 mg Sublingual Tabs1.24USD tab
Symax fastabs 0.125 mg tablet1.21USD tablet
Symax-sl 0.125 mg tablet sl1.17USD tablet
Levsin 0.125 mg tablet1.08USD tablet
Levsin-sl 0.125 mg tablet sl0.97USD tablet
Hyoscyamine Sulfate 0.125 mg tablet0.93USD tablet
Nulev 0.125 mg tablet0.91USD tablet
Hyoscyamine Sulfate 0.125 mg Sublingual Tabs0.88USD tab
Hyomax-sl 0.125 mg tablet sl0.86USD tablet
Hyoscyamine Sulfate 0.125 mg Dispersible Tablet0.83USD dispersible tablet
Hyoscyamine sulf 0.125 mg tablet0.79USD tablet
Hyoscyamine su 0.125 mg tablet0.64USD tablet
Hyoscyamine 0.125 mg tablet sl0.53USD tablet
Hyoscyamine sul 0.15 mg tablet sl0.39USD tablet
Anaspaz 0.125 mg Dispersible Tablet0.36USD dispersible tablet
Levsin 0.125 mg/5ml Elixir0.29USD ml
Anaspaz 0.125 mg tablet sl0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)108.5 °CPhysProp
water solubility3560 mg/L (at 20 °C)MERCK INDEX (1996); pH 9.5
logP1.8Not Available
logS-1.91ADME Research, USCD
pKa11.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility2.52 mg/mLALOGPS
logP2.19ALOGPS
logP1.57ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)9.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity80.82 m3·mol-1ChemAxon
Polarizability31.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9286
Blood Brain Barrier+0.9569
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.6542
P-glycoprotein inhibitor IINon-inhibitor0.8595
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7041
CYP450 2D6 substrateNon-substrate0.6838
CYP450 3A4 substrateSubstrate0.5496
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9275
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.95
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9113
Ames testNon AMES toxic0.7742
CarcinogenicityNon-carcinogens0.9631
BiodegradationReady biodegradable0.5527
Rat acute toxicity2.7305 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8354
hERG inhibition (predictor II)Inhibitor0.5378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.14 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00di-9810000000-bdd60b3a23f97899d426
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-6951100000-43127e046c478d2643e1
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]octane.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Tropane alkaloids
Sub Class
Not Available
Direct Parent
Tropane alkaloids
Alternative Parents
Beta hydroxy acids and derivatives / Piperidines / N-alkylpyrrolidines / Benzene and substituted derivatives / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Azacyclic compounds / Primary alcohols
show 4 more
Substituents
Tropane alkaloid / Beta-hydroxy acid / Monocyclic benzene moiety / Hydroxy acid / Piperidine / Benzenoid / N-alkylpyrrolidine / Pyrrolidine / Amino acid or derivatives / Carboxylic acid ester
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate (CHEBI:17486) / Tropane alkaloids, Tropan alkaloids (C02046)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Huang XP, Williams FE, Peseckis SM, Messer WS Jr: Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain. J Pharmacol Exp Ther. 1998 Sep;286(3):1129-39. [PubMed:9732369]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94. [PubMed:11495349]

Drug created on June 13, 2005 07:24 / Updated on December 12, 2018 07:25